Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
April-2016 Volume 13 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
April-2016 Volume 13 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway

  • Authors:
    • Xiangxiu Sun
    • Lin Lin
    • Ying Chen
    • Tianfeng Liu
    • Ronghua Liu
    • Zhongde Wang
    • Kai Mou
    • Jia Xu
    • Bo Li
    • Haibo Song
  • View Affiliations / Copyright

    Affiliations: Department of Gynecology and Obsterics, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Prenatal Diagnosis Center, Zibo Maternal and Child Health Hospital, Zibo, Shandong 255000, P.R. China, Department of Cardiology, Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China
  • Pages: 3161-3168
    |
    Published online on: February 23, 2016
       https://doi.org/10.3892/mmr.2016.4929
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Nitidine chloride (NC) has been demonstrated to exert anti-tumor effects on various types of tumor. However, no studies have investigated the anti‑metastatic effect of NC on ovarian cancer cells, and the underlying mechanisms have not yet been clearly established. The present study aimed to determine the effect of NC on the migration and invasion of ovarian cancer cells. Cell viability and proliferation of ovarian cancer cells were assessed by MTT assay. A scratch wound healing assay and Transwell assays were performed to detect migration and invasion of cells, respectively. The expression levels of matrix metalloproteinase (MMP)‑2 and 9 were detected at the mRNA and protein level following stimulation with NC. Subsequently, the expression of mitogen‑activated protein kinases was detected by western blot analysis. Finally, an inhibitor of extracellular signal‑regulated kinase (ERK) was applied to investigate the effect of NC on the expression of MMP‑2/9 as well as the migration and invasion of cells. It was found that NC suppressed the proliferation, migration and invasion of A2780 ovarian cancer cells. NC downregulated MMP‑2 and MMP‑9 in a dose‑ and time‑dependent manner. In addition, NC was also able to downregulate phosphorylation of ERK. Furthermore, by applying an ERK inhibitor, U0126, the effect of NC on the expression of MMP-2/9 and inhibition of cell migration and invasion was verified. Taken together, these results demonstrated that NC inhibited the migration and invasion of ovarian cancer cells via the ERK signaling pathway.

Introduction

Ovarian cancer is the second most common gynecological malignancy and the fifth most frequent cause of cancer-associated mortality in females worldwide, with >2 million new cases and 1 million mortalities in 2013 (1,2). At present, surgery followed by chemotherapy is the current standard treatment for localized ovarian cancer. However, the highly invasive property and difficulty of detection of early-stage ovarian cancer leads to a poor prognosis (3). As a result, only 40% of patients in all stages survive and 70–80% of patients with distant metastases succumb to the disease within 5 years of diagnosis (4,5). Thus, the therapeutic options for metastatic ovarian cancer remain limited. Therefore, there is an urgent need to elucidate the molecular mechanisms and to identify novel agents for ovarian cancer patients to obtain an improved treatment outcome.

Increasing evidence has demonstrated the pivotal role of the extracellular matrix (ECM) and matrix metalloproteinases (MMPs) in cancer invasion and metastasis (6,7). As a family of structurally conserved, zinc-dependent endopeptidases, the MMPs are important in proteolysis of the ECM. Among them, MMP-2/9 can degrade components of the ECM and thus eliminate the barrier that restrains cancer invasion (8,9). Mitogen-activated protein kinase (MAPK) family members, including extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK), have been demonstrated to be crucial in mediating MMP2/9 production (10,11).

In previous years, natural products have obtained increasing attention as new anti-tumor therapeutic drugs due to their relatively few side effects (12). Among them, nitidine chloride (NC; Fig. 1A) is a natural bioactive phytochemical alkaloid derived from the root of Zanthoxylum nitidum (Roxb). Previous studies have demonstrated that NC has anti-inflammatory, anti-oxidant, anti-fungal and anti-HIV functions (13,14). NC has been demonstrated to have anti-tumor activity in different types of cancer. NC can induce apoptosis and inhibit the growth and metastasis of renal cancer (15,16). NC was also found to suppress the proliferation of hepatocellular carcinoma (17). Another study demonstrated that NC is able to inhibit the growth of gastric cancer via the signal transducer and activator of transcription 3 signaling pathway (18). In addition, NC is able to suppress the growth of breast cancer and inhibit its metastasis through the c-Src/focal adhesion kinase pathway (19,20). However, to the best of our knowledge, no studies have investigated whether NC has a direct effect on ovarian cancer migration and invasion or the mechanisms of this effect.

Figure 1

Chemical structure of NC and the effect of NC on A2780 ovarian cancer cell proliferation. (A) Chemical structure of NC. (B) Following treatment with NC for 24 h at different concentrations (0, 1, 2.5, 5 and 10 µM), the viability of A2780 cells was determined by an MTT assay. (C) Following treatment with 0, 5 and 10 µM NC for different time periods (0, 6, 12, 24 and 48 h), an MTT assay was used to detect the viability of A2780 cells. The results are presented as the mean ± standard deviation from three independent experiments. *P<0.05, **P<0.01 vs. the control group (0 µM NC). NC, nitidine chloride; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide.

In the present study, the effects of NC on ovarian cancer cell migration and invasion, as well as the underlying molecular mechanisms were evaluated.

Materials and methods

Cell lines and reagents

The human A2780 ovarian cancer cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and cells were routinely cultured in RPMI-1640 containing 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin (Macgene Biotechnology Ltd., Beijing, China) in 5% CO2 at 37°C. Monoclonal rabbit anti-human ERK1/2 (cat. no. 4695; 1:1,000 dilution), monoclonal rabbit anti-human phospho-ERK1/2 (cat. no. 4370; 1:1,000 dilution), monoclonal rabbit anti-human p38 (cat. no. 8690; 1:1000 dilution), monoclonal rabbit anti-human phospho-p38 (cat. no. 4631; 1:1,000 dilution), monoclonal rabbit anti-human JNK (cat. no. 9252; 1:1,000 dilution), monoclonal rabbit anti-human phospho-JNK (cat. no. 4668; 1:1,000 dilution), monoclonal rabbit anti-human MMP-2 (cat. no. 13132; 1:1,000 dilution) and monoclonal rabbit anti-human MMP-9 (cat. no. 13667; 1:1,000 dilution) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). NC was purchased from Shanghai Tauto Biotech Co., Ltd. (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO). U0126, a selective inhibitor of ERK, was purchased from Sigma-Aldrich (St. Louis, MO, USA).

MTT assay of cell viability and proliferation

Cell viability and proliferation were assessed using a 3-(4,5-dimethylthi-azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Beyotime Institute of Biotechnology, Haimen, China) assay. A2780 cells (5,000 cells/well) in 100 µl medium were seeded into 96-well plates. Following stimulation with NC of various concentrations (0, 1, 2.5, 5 and 10 µM) for various times (0, 6, 12, 24 and 48 h), 20 µl MTT (5 mg/ml) was added into each well. Following incubation for 4 h at 37°C, 100 µl of DMSO was added to each well for another 15 min. Finally, the absorbance values were determined using a microplate luminometer (iMark; Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 490 nm. A2780 cells stimulated with 0 µM NC at various time points (0, 6, 12, 24 and 48 h) were used as the control group.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from A2780 cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and then reverse transcribed to cDNA using a RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. qPCR analysis was performed using a LightCycler (Bio-Rad Laboratories Inc.). The primer sequences used for qPCR were as follows: MMP-2, forward: 5′-TTG ATG GCA TCG CTC AGA TC-3′ and reverse: 5′-TTG TCA CGT GGC GTC ACA GT-3′; MMP-9, forward: 5′-GAC GCA GAC ATC GTC ATC CA-3′ and reverse: 5′-CAC AAC TCG TCA TCG TCG AAA-3′. The cycling conditions were as follows: 95°C for 10 sec, followed by 40 cycles of 95°C for 5 sec, 60°C for 30 sec and a final extension at 72°C for 3 min. SYBR Green I was purchased from Invitrogen (Thermo Fisher Scientific, Inc.) Melting curves were assessed to confirm the specificity of the products generated for each set of primers. Following amplification, the ΔΔCq comparative method was then used to normalize the relative levels of gene expression to GAPDH (21). Experiments were performed in triplicate.

Western blot analysis

Following treatment, the cells were harvested and then the protein was extracted using protein lysis buffer (Beyotime Institute of Biotechnology). Centrifugation was performed at 10,000 × g for 15 min at 4°C. Total cell protein concentrations were determined using the bicinchoninic acid protein assay kit (Pierce Biotechnology Inc., Rockford, IL, USA). Equal protein from cell lysates was loaded onto 12% SDS-PAGE gels (Bio-Rad Laboratories, Inc.). Following electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA) and then blocked with 5% fat-free milk at room temperature for 1 h, and incubated with the indicated primary antibodies overnight at 4°C. Subsequently, the membranes were washed with Tris-buffered saline and Tween 20 and incubated with polyclonal goat anti-rabbit horseradish peroxidase-conjugated IgG (cat. no. ZDR-5306; 1:10,000 dilution; ZSGB-BIO, Beijing, China) secondary antibody for 1 h at room temperature. Immune complexes were detected with enhanced chemiluminescence reagents and the blots were quantified by densitometric analysis using the Alpha Imager 2200 (Alpha Innotech Corp., Santa Clara, CA, USA). Reactions were performed once per PVDF membrane.

Scratch wound healing assay

A scratch wound healing assay was used to assess the migration ability of the A2780 cells. In brief, the A2780 cells (1×106/well) were seeded in 6-well plates and cultured with RPMI-1640 supplemented with 10% FBS. When reaching confluency, each well was scratched with a 200 µl pipette tip. To assess the effects of NC on the migration of A2780 cells, 5 µM NC was added to the plates. After 24 h of incubation, images of the wound healing areas were captured and then the distance between two cell edges was analyzed by ImageJ software (version 1.48; National Institutes of Health, Bethesda, MD, USA).

In vitro invasion assay

To evaluate the effect of NC on the invasive ability of A2780 cells, the transwell system was used. A2780 cells were cultured in Boyden chambers, with 8-µm pore filter inserts, in 24-well plates (Corning Life Sciences, Corning, NY, USA). The pore inserts were pre-coated with Matrigel (BD Biosciences, San Jose, CA, USA) overnight. A2780 cells (1×105 cells/well) were suspended in 100 µl RPMI-1640 supplemented with 1% FBS and added to the upper chamber. RPMI-1640 with 10% FBS and 5 µM NC were added to the lower chamber. The cells on the top of the membrane were gently scraped using a swab. After 24 h of incubation at 37°C, the cells attaching to the lower surface were fixed with methanol and stained with 0.1% crystal violet (Beyotime Institute of Biotechnology) for 15 min at room temperature. A total of five random high-power fields (magnification, ×200; Nikon E100; Nikon Corp, Tokyo, Japan) of each sample were selected and counted to evaluate the average number of invasive cells.

In vitro migration assay

For the migration assay, cells were added to upper chambers without coated Matrigel. The assay was performed as described above for the invasion assay. The cells on the lower surface were also counted in five randomly selected fields and then the cell number was analyzed statistically.

Statistical analysis

The data are expressed as the mean ± standard deviation. All experiments were repeated at least three times. Comparisons among values for all groups were performed by one-way analysis of variance. Holm's t-test was used for analysis of differences between different groups. P<0.05 was considered to indicate a statistically significant difference.

Results

NC inhibits the cell viability of ovarian cancer cells

The structure of NC is shown in Fig. 1A. To determine the specific role of NC on the cell viability of A2780 cells, an MTT assay was used as described in Materials and methods. As shown in Fig. 1B, various concentrations (0, 1, 2.5, 5 and 10 µM) of NC were added to the cultured A2780 cells. At a dose of 10 µM, NC significantly inhibited the viability of A2780 cells after 24 h incubation. However, at concentrations <10 µM (1, 2.5 and 5 µM), the inhibitory effect was not significant. Furthermore, 5 and 10 µM NC were selected to stimulate the cells at different time points (0, 6, 12, 24 and 48 h). As shown in Fig. 1C, after 24 h stimulation, NC significantly inhibited the cell viability at a dose of 10 µM, while 5 µM NC did not significantly inhibit cell viability. However, after 48 h stimulation, 5 and 10 µM NC significantly inhibited cell viability. As a result, 5 µM NC for 24 h was selected in the subsequent migration and invasion experiments in order to exclude the effect of cell viability.

NC inhibits the migration and invasion of ovarian cancer cells

The wound healing assay was used to investigate the effect of NC on the migration of ovarian cancer cells. A2780 ovarian cancer cells were treated with NC at a concentration of 5 µM for 24 h. As shown in Fig. 2A, migration of A2780 cells was inhibited by NC (5 µM). The results of the wound healing assay demonstrated that healing over the scratch was significantly deceased following treatment with NC. In order to further examine the effect of NC on cell migration and invasion, a Transwell assay was performed. A2780 cells were treated with NC at a concentration of 5 µM for 24 h. As shown in Fig. 2B, the migration and invasion of A2780 cells were significantly inhibited by NC (5 µM). The results of the Transwell assay indicated that NC could inhibit the migratory and invasive ability of ovarian cancer cells.

Figure 2

NC inhibits the migration and invasion of A2780 ovarian cancer cells. (A) A2780 cells were treated with NC at a concentration of 5 µM for 24 h and then assessed by a wound healing assay. (B) A2780 cells were treated with NC at concentrations of 5 µM for 24 h. The effect of NC on the migration and invasion of A2780 ovarian cancer cells was assessed by a Transwell assay. The bar graph represents the results of three independent experiments. **P<0.01 vs. the control group. NC, nitidine chloride.

NC downregulates the expression of MMP-2/9 in ovarian cancer cells

Numerous evidence has supported that MMPs, particularly MMP-2 and MMP-9, are important in the process of cancer cell migration and invasion (22,23). The present study thus determined the effect of NC on MMP-2 and MMP-9 expression in A2780 ovarian cancer cells. Various concentrations of NC (0, 2.5, 5 and 10 µM) were added to the A2780 cells, respectively, and the cells were then cultured for another 24 h. As shown in Fig. 3A, NC treatment significantly decreased the expression of MMP-2 and MMP-9 in A2780 cells at a concentration of 5 and 10 µM. The A2780 cells were then stimulated with 5 µM NC for different time periods (0, 6, 12 and 24 h). As shown in Fig. 3B, following stimulation with 5 µM NC for 6 h, the expression of MMP-2 and MMP-9 was not altered. However, when the stimulating time was extended to 12 and 24 h, the expression of MMP-2 and MMP-9 was significantly decreased compared with the control group. In addition, identical treatments were performed and qPCR was applied to detect the mRNA levels of MMP-2 and MMP-9. As shown in Fig. 3C, the relative mRNA expression of MMP-2 and MMP-9 was significantly decreased when treated with 5 and 10 µM NC. Similar to the protein level, it also decreased gradually following stimulation with 5 µM for 6, 12 and 24 h (Fig. 3D). The results above suggest that NC inhibited the production of MMP-2 and MMP-9 in a dose- and time-dependent manner at the mRNA and protein levels. The results above also indicate that the inhibitory effect of NC on A2780 cell invasion and migration may be associated with MMP-2 and MMP-9 production.

Figure 3

NC decreases the expression of MMP-2 and MMP-9 in A2780 ovarian cancer cells. (A and C) A2780 cells were treated with NC at different concentrations (0, 2.5, 5 and 10 µM) for 24 h and the level of MMP-2 and MMP-9 expression was determined by western blot analysis and qPCR. (B and D) A2780 cells were stimulated with 5 µM NC for different time periods (0, 6, 12 and 24 h) and the level of MMP-2 and MMP-9 expression was determined by western blot analysis and qPCR. *P<0.05 and **P<0.01 vs. the control group. Data are presented as the mean ± standard deviation from three independent experiments. NC, nitidine chloride; MMP, matrix metalloproteinase; qPCR, quantitative polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

ERK1/2 signaling pathway mediates inhibition of MMP-2/9 production following treatment with NC

The MAPK signaling pathway is important in the development of various types of cancer. Inhibition of MAPK activation has been demonstrated to suppress tumor cell migration and invasion (24). To determine the association between NC and the production of MMP-2 and MMP-9, the relative expression of three members of the MAPK family, including phospho-JNK, phospho-p38 and phospho-ERK1/2 were investigated following treatment of A2780 cells with 5 µM NC for 0, 5, 15, 30 and 60 min. As shown in Fig. 4A and B, the relative expression of phospho-ERK1/2 was significantly downregulated compared with the control group. The activity of phospho-ERK1/2 rapidly decreased after 5–30 min stimulation and gradually increased after 1 h stimulation. However, the expression of phospho-JNK and phospho-p38 was not altered. The results above suggested that the ERK pathway may be involved in MMP-2 and MMP-9 production of ovarian cancer cells.

Figure 4

ERK1/2, but not p38 or JNK, regulates NC-mediated production of MMP-2 and MMP-9 in A2780 ovarian cancer cells. (A) A2780 cells were stimulated with 5 µM NC for different time periods (0, 5, 15, 30 and 60 min) and the levels of p-ERK1/2, ERK1/2, p-p38, p38, p-JNK and JNK were analyzed by western blotting. (B) Statistical analysis of the western blotting results. *P<0.05, **P<0.01 vs. the control group. (C) A2780 cells were treated with NC (5 µM) for 24 h and U0126 (10 µM) was added to A2780 cells 1 h prior to NC treatment. The levels of p-ERK1/2, ERK1/2, MMP-2 and MMP-9 were analyzed by western blot analysis with GAPDH as a control. (D) Statistical analysis of the western blotting results. *P<0.05, **P<0.01 vs. the control group; #P<0.05, ##P<0.01, compared with the cells treated with NC. Data are presented as the mean ± standard deviation from three independent experiments. NC, nitidine chloride; MMP, matrix metalloproteinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; t-, total.

To further investigate whether the effect of NC is ERK-dependent, U0126 (ERK inhibitor) was applied to inhibit ERK activation. As shown in Fig. 4C and D, inhibition of ERK activity with U0126 could further downregulate the expression of MMP-2 and MMP-9 compared with NC treatment. These results further demonstrated that NC-inhibited MMP-2 and MMP-9 production may be ERK dependent.

Inhibition of the ERK pathway enhanced the anti-metastatic effect of NC in ovarian cancer cells

To further investigate whether the anti-metastatic effect of NC was attributed to ERK signaling suppression, the effect of U0126 on A2780 cell migration in the presence or absence of NC was examined. As shown in Fig. 5A, the results of the wound healing assay demonstrated that the NC-induced inhibition of wound healing was significantly enhanced by using an ERK inhibitor. Similar results were observed using the Transwell assay (Fig. 5B), which also demonstrated that inhibition of ERK activation could significantly enhance the NC-induced inhibition of ovarian cancer cell invasion. These results above support the theory that suppression of metastasis by NC is regulated by inhibition of MMP-2/9 production though the ERK signaling pathway in ovarian cancer cells.

Figure 5

Inhibition of extracellular signal-regulated kinase 1/2 signaling enhances the anti-metastatic effect of NC in A2780 ovarian cancer cells. (A) A2780 cells were treated with NC (5 µM) and/or U0126 (10 µM) for 24 h, and then assessed by a wound healing assay. (B) A2780 cells were treated with NC (5 µM) and/or U0126 (10 µM) for 24 h. The effect of NC on the invasion of A2780 ovarian cancer cells was assessed by a Transwell assay. The results are presented as the mean ± standard deviation from three independent experiments. **P<0.01 vs. the control group; #P<0.05, ##P<0.01, compared with the cells treated with NC. NC, nitidine chloride.

Discussion

Metastasis is considered the primary cause of mortality in the majority of cancer patients and is one of the most crucial issues in cancer research. Therefore, it is important to examine the molecular mechanisms of metastasis and to identify effective agents to inhibit cancer metastasis. However, traditional chemotherapeutics are restricted in long-term application due to their toxicity and side effects. There has been increasing attention on natural drugs in tumor therapy with fewer side effects (25,26). Accumulating evidence has demonstrated that NC possesses the capacity to inhibit the proliferation, migration and invasion and/or induce the apoptosis of breast, renal, gastric and hepatocellular cancer cells (15–20). Although previous studies have revealed the anti-tumor efficacy of NC, whether NC has any effect on ovarian cancer cell migration and invasion, as well as the detailed molecular mechanisms have not been elucidated. The present study initially evaluated the effect of NC on the viability of cultured ovarian cancer cells and the results revealed that 5 µM NC significantly inhibited cell proliferation after 48 h of incubation, while no difference was observed before 24 h. As a result, 24 h was selected as the stimulation time period and 5 µM as the stimulation concentration for the following experiments involving cell migration and invasion, in order to exclude the effect of proliferation. To the best of our knowledge, the present study demonstrated for the first time that NC could effectively inhibit ovarian cancer cell migration and invasion. Furthermore, NC inhibited ovarian cancer cell migration and invasion by suppressing MMP-2 and MMP-9 production via the ERK signaling pathway. The present study provided a novel molecular mechanism explaining how NC exhibits its anti-tumor effect on ovarian cancer cells.

The metastasis and invasion of ovarian cancer is a complicated and multi-step process that is mediated by numerous factors. MMPs are proteinases that are crucial for malignant cells in the proteolytic degradation of the basement membrane and ECM, in order for malignant cells to migrate and invade into surrounding tissues (22,23). Among these, the role of MMP-2 and MMP-9 has been underlined; their type IV collagenase activity is essential during the initial period of metastasis and invasion (8,9). Increased expression of MMP-2 and MMP-9 was associated with a poor prognosis in ovarian cancer patients (27,28). The suppressive role of NC on the migration and invasion of A2780 ovarian cancer cells was then evaluated via scratch wound healing and Transwell assays. Furthermore, the decreased expression of MMP-2 and MMP-9 observed following NC treatment was associated with the inhibition of migration and invasion in A2780 ovarian cancer cells. Therefore, the finding that NC downregulated the expression of MMP-2 and MMP-9, may show a potential association between the inhibition of metastasis by NC and MMP activity.

Several studies have reported that MAPK family members, including ERK, p38 and JNK, can lead to MMP2/9 production and potentially promote the proliferation and metastasis of tumors (10,11,29). As one of the crucial signal transduction pathways, the ERK signaling pathway is involved in the regulation of proliferation, apoptosis, migration and invasion of cancer cells (30–32). In the present study, the ERK activity in ovarian cancer cells was assessed by western blot analysis. The results demonstrated that the expression of phospho-ERK was downregulated following treatment with NC. To verify that the ERK signaling pathway was involved in the inhibition of ovarian cancer cell migration and invasion by NC, ERK activity was inhibited by applying the ERK inhibitor U0126. It was found that suppression of ERK phosphorylation by U0126 enhanced MMP2/9 downregulation induced by NC. In addition, inhibition of ERK activity further inhibited cell migration and invasion. These results suggested that NC suppressed ovarian cancer cell migration and invasion through inhibiting ERK activity and decreasing the production of MMP-2/9. The results demonstrated that applying the ERK inhibitor U0126 enhanced NC-induced downregulation of MMP-2/9, further demonstrating that ERK was upstream of MMP-2/9.

In conclusion, to the best of our knowledge, the present study indicated for the first time that NC inhibited the migration and invasion of ovarian cancer cells by suppressing MMP-2/9 production. Furthermore, the effect of NC was regulated by the ERK signaling pathway. Therefore, our findings suggested that NC is a possible drug for ovarian cancer therapy. However, further in vivo research is required.

References

1 

Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Sun ZL, Tang YJ, Wu WG, Xing J, He YF, Xin DM, Yu YL, Yang Y and Han P: AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3 cells in vitro. Asian Pac J Cancer Prev. 14:4823–4827. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Stallings-Mann M and Radisky D: Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs. 185:104–110. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Liotta LA and Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol. 1:99–106. 1990.PubMed/NCBI

9 

Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW and Muschel RJ: Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis. 14:246–258. 1994.PubMed/NCBI

10 

Kim BS, Park JY, Kang HJ, Kim HJ and Lee J: Fucoidan/FGF-2 induces angiogenesis through JNK- and p38-mediated activation of AKT/MMP-2 signalling. Biochem Biophys Res Commun. 450:1333–1338. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Jin YJ, Park I, Hong IK, Byun HJ, Choi J, Kim YM and Lee H: Fibronectin and vitronectin induce AP-1-mediated matrix metal-loproteinase-9 expression through integrin alpha α(5)β(1)/α(v) β(3)-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells. Cell Signal. 23:125–134. 2011. View Article : Google Scholar

12 

Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Wang Z, Jiang W, Zhang Z, Qian M and Du B: Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappab pathway in RAW 264.7 cells. J Ethnopharmacol. 144:145–150. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME and Perfect JR: Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother. 43:2862–2868. 1999.PubMed/NCBI

15 

Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, Xu Z and Liu Z: Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via suppressing ERK signaling pathway in renal cancer. Food Chem Toxicol. 66:210–216. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, Shi B, Xu Z and Liu Z: Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 60:246–251. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu DB and Peng J: Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 32:79–84. 2013.PubMed/NCBI

18 

Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X and Liu M: Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther. 11:277–287. 2012. View Article : Google Scholar

19 

Pan X, Han H, Wang L, Yang L, Li R, Li Z, Liu J, Zhao Q, Qian M, Liu M and Du B: Nitidine Chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett. 313:181–191. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Sun M, Zhang N, Wang X, Cai C, Cun J, Li Y, Lv S and Yang Q: Nitidine chloride induces apoptosis, cell cycle arrest, and synergistic cytotoxicity with doxorubicin in breast cancer cells. Tumour Biol. 35:10201–10212. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, Qi L, Zhang M, Wang X, Cui T, Yang LJ, et al: Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. 63:514–525. 2014. View Article : Google Scholar

22 

Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar

23 

Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.PubMed/NCBI

24 

Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J and Tiwari RK: 3,3′-diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep. 25:491–497. 2011.

25 

Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP and Gescher AJ: Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer. 120:451–458. 2007. View Article : Google Scholar

27 

Li LN, Zhou X, Gu Y and Yan J: Prognostic value of MMP-9 in ovarian cancer: A meta-analysis. Asian Pac J Cancer Prev. 14:4107–4113. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Fu Z, Xu S, Xu Y, Ma J, Li J and Xu P: The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer. 25:356–362. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Thompson N and Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 5:350–356. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Gendron S, Couture J and Aoudjit F: Integrin alpha2beta1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem. 278:48633–48643. 2003. View Article : Google Scholar : PubMed/NCBI

31 

Shelton JG, Steelman LS, White ER and McCubrey JA: Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle. 3:372–379. 2004.PubMed/NCBI

32 

Ono H, Basson MD and Ito H: PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. PloS One. 9:e960602014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sun X, Lin L, Chen Y, Liu T, Liu R, Wang Z, Mou K, Xu J, Li B, Song H, Song H, et al: Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway. Mol Med Rep 13: 3161-3168, 2016.
APA
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z. ... Song, H. (2016). Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway. Molecular Medicine Reports, 13, 3161-3168. https://doi.org/10.3892/mmr.2016.4929
MLA
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z., Mou, K., Xu, J., Li, B., Song, H."Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway". Molecular Medicine Reports 13.4 (2016): 3161-3168.
Chicago
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z., Mou, K., Xu, J., Li, B., Song, H."Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway". Molecular Medicine Reports 13, no. 4 (2016): 3161-3168. https://doi.org/10.3892/mmr.2016.4929
Copy and paste a formatted citation
x
Spandidos Publications style
Sun X, Lin L, Chen Y, Liu T, Liu R, Wang Z, Mou K, Xu J, Li B, Song H, Song H, et al: Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway. Mol Med Rep 13: 3161-3168, 2016.
APA
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z. ... Song, H. (2016). Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway. Molecular Medicine Reports, 13, 3161-3168. https://doi.org/10.3892/mmr.2016.4929
MLA
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z., Mou, K., Xu, J., Li, B., Song, H."Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway". Molecular Medicine Reports 13.4 (2016): 3161-3168.
Chicago
Sun, X., Lin, L., Chen, Y., Liu, T., Liu, R., Wang, Z., Mou, K., Xu, J., Li, B., Song, H."Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway". Molecular Medicine Reports 13, no. 4 (2016): 3161-3168. https://doi.org/10.3892/mmr.2016.4929
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team